Fri. Nov 20th, 2026

Leading clinicians and guideline bodies say ADHD medications warrant sensible cardiovascular screening, but insist that routine electrocardiograms for all patients are unnecessary and could distract from delivering targeted, evidence-led care.

Attention-deficit hyperactivity disorder affects large numbers of children and adults, and stimulant medications such as methylphenidate and lisdexamfetamine remain effective treatments for many patients. These medicines can raise heart rate and blood pressure, so clinicians agree cardiovascular history-taking, blood-pressure measurement and pulse checks are essential before starting treatment and during follow-up. However, specialists warn that equating those routine checks with a universal requirement for pre-treatment ECGs misreads clinical guidance and risks fuelling unnecessary alarm.

Experts emphasise a proportionate, risk-based approach. Most people with undiagnosed minor congenital heart differences will not experience adverse events with properly monitored ADHD treatment, and serious cardiac complications are uncommon. Clinicians therefore recommend focused investigation—such as an ECG or cardiology referral—when a patient has a concerning personal or family cardiac history, symptoms such as syncope or palpitations, abnormal examination findings, or when other medications raise cardiac risk. Applying the heavier diagnostic pathway only where clinically indicated preserves NHS resources while directing specialist assessment to those most likely to benefit.

The debate has a practical policy angle. Frontline prescribers should have clear, consistently applied pathways so that cardiovascular assessment is reliably performed and escalated when needed. That means ensuring primary-care clinicians and specialist services document cardiovascular history and vital signs at baseline and follow-up, and that local referral routes to cardiology are accessible for patients with red flags. Clinicians say this operational work—improving consistency and follow-through—will do more to reduce harm than mandating routine ECGs for every patient starting ADHD medication.

Public messaging matters too. Framing the safety issue in alarmist terms can deter patients who would benefit from treatment and can undermine trust in services. Clear, factual communication that outlines what checks are reasonable, when extra tests are warranted, and how patients who develop concerning symptoms should seek urgent review will better serve public health and individual care.

Finally, clinicians call for proportionate data collection and research to monitor rare adverse events and to refine screening recommendations over time. Ongoing surveillance and locally audited practice will help ensure that screening protocols remain evidence-based and that patients receive effective treatment with appropriate safeguards.